Novartis raises 2026 profit guidance on Q3 growth despite pipeline setbacks
According to TradingView, Novartis Q3 sales rose 4% and core operating income 10%, and FY2026 profit guidance was raised despite pipeline setbacks.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, Novartis reported third-quarter sales up 4% and core operating income up 10%. That allowed the company to lift its profit guidance for fiscal 2026.
Growth drivers and new launches offset pressure from generics. However, setbacks for del-desiran and pelacarsen weighed on reported results and the outlook for the pipeline.
why it matters
Traders will weigh the higher guidance, which supports earnings expectations, against pipeline setbacks that cloud future sales. The news is mainly relevant for Novartis shares.
market impact
Novartis shares: higher guidance supports the stock, pipeline setbacks weigh on it
- Novartis shares mixed — higher profit guidance supports the stock while drug setbacks pressure it
tags
instruments
sources
- NOVN: Strong growth drivers lifted Q3 profit and FY2026 guidance despite pipeline setbacks — TradingView, 27 October 2026 at 23:27 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗